The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London pre-open: Footsie to recoup losses

Tue, 18th Aug 2009 07:44

Footsie is expected to win back some of the heavy losses it posted yesterday.British Land saw the value of its property portfolio fall to £8.18bn in the first quarter but said the pace of decline has slowed markedly. The group, which has been the subject of intense bid speculation, said £3.2bn (39%) of assets either increased (£1.7bn) or are unchanged (£1.5bn) in value since March 2009.Cash strapped miner Rio Tinto has received a $2.025bn offer for the majority of its Alcan Packaging business. The binding offer has been received from Amcor and covers the Alcan Packaging global pharmaceuticals, global tobacco, food Europe and food Asia divisions. The deal does not include the remaining Beaty packaging division which will be sold off separately.A joint venture including support services firm Carillion has won a 'Building Schools for the Future' contract for Durham. The Local Education Partnership (LEP), comprising Carilliom, Durham County Council and Building Schools for the Future Investments LLP, will deliver more than 40 schools in four phases over a 10-year contract period under the terms of the £500m programme.Car dealer Pendragon reported sharply lower profits in the six months to June 30 as recession-hit motorists held onto their old cars rather than splashing out on new ones. It posted a pre-tax profit of £11.4m, compared with £21.1m over the same period the previous year, as revenue slid to £1.59bn from £2.48bn.Respiratory inhaler firm Vectura remains "very confident" about prospects with important drug trials due to start later this year and plenty of cash in the bank. Phase III trials of QVA149 to treat chronic obstructive pulmonary disease are expected to start in late 2009. The drug combines Vectura's NVA237 and indacaterol (QAB149), developed by Swiss group Novartis.Online video services provider Amino Technologies posted an operating loss compared with a profit the same time a year before as challenging economic conditions continued hit the group. The group reported an operating loss before exceptional items of £3.10m for the six months ended 31 May 2009 compared with an operating profit £0.61m before.Nightclub owner Luminar can breathe a little easier on news that 95.5% of the shares available through an open offer have been taken up and buyers have been found for the remainder. The group raised £37.5m (£35.7m net) from a firm placing and open offer at 95p a share. Just 920,000 of the 19.4m shares available through the open offer were unwanted by shareholders.
More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.